Clinical Research Directory
Browse clinical research sites, groups, and studies.
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
Sponsor: Yale University
Summary
The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.
Official title: Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment - A Pragmatic Hybrid Effectiveness/Implementation Trial
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2024-06-04
Completion Date
2029-05
Last Updated
2025-10-30
Healthy Volunteers
No
Conditions
Interventions
Methadone
Drug: Methadone Possible formulations: 10 and 50 mg tablets
Buprenorphine (BUP)
Drug: Buprenorphine (BUP) Possible formulations: A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day B. Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade) 8 mg q 7 days (Brixadi) 16 mg q 7 days (Brixadi) 24 mg q 7 days (Brixadi) 32 mg q 7 days (Brixadi) 64 mg q 7 28 days (Brixadi) 96 mg q 7 28 days (Brixadi) 128 mg q 7 28 days (Brixadi)
Locations (6)
Highland Hospital Bridge Clinic at Alameda Health System
Oakland, California, United States
Outpatient Buprenorphine Induction Clinic, University of California, San Francisco
San Francisco, California, United States
Rapid Start Clinic, Kaiser Permanente Colorado
Denver, Colorado, United States
Officed Based Addiction Treatment Program, Boston Medical Center
Boston, Massachusetts, United States
Hennepin Healthcare Addiction Medicine
Minneapolis, Minnesota, United States
Marshall University Division of Addiction Sciences P.R.O.A.C.T
Huntington, West Virginia, United States